Home ›
NPI 1801844063
NPI deactivated
1801844063
1801844063 was paid $451K by Medicaid between Jan 2018 and Jun 2022, across 29 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 34% of everything it billed.
33Billing provider info1801844063
33aNPI1801844063
33bProvider type—
28Total paid$451K
24GClaims10,942
24DCodes billed29
24AFirst – last monthJan 2018 – Jun 2022
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,067 | $82K | |
| 2019 | 2,133 | $93K | |
| 2020 | 2,074 | $74K | |
| 2021 | 3,708 | $151K | |
| 2022 | 960 | $51K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 34% | 3,280 | 2,625 | $153K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 16% | 978 | 875 | $73K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 13% | 769 | 428 | $60K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.7% | 364 | 287 | $26K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.6% | 342 | 283 | $25K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 5.1% | 502 | 415 | $23K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 4.9% | 270 | 201 | $22K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 3.2% | 776 | 690 | $14K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.9% | 253 | 218 | $13K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.3% | 143 | 134 | $10K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.7% | 108 | 97 | $8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.6% | 300 | 281 | $7K |
17 more codes
| 96127 | 1.2% | 373 | $5K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 168 | $3K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 74 | $2K |
| 80061 | Lipid panel | <1% | 199 | $1K |
| 87081 | <1% | 136 | $1K | |
| 85018 | <1% | 420 | $964.19 | |
| 36416 | <1% | 252 | $758.50 | |
| 0002A | <1% | 15 | $600.00 | |
| 0001A | <1% | 15 | $600.00 | |
| 83655 | <1% | 50 | $581.14 | |
| 82947 | <1% | 32 | $122.24 | |
| 94760 | <1% | 38 | $4.40 | |
| 91300 | <1% | 29 | $0.29 | |
| 1003F | 0% | 433 | $0.00 | |
| 99072 | 0% | 233 | $0.00 | |
| 1220F | 0% | 195 | $0.00 | |
| 1036F | 0% | 195 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.